SELDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of a boosting decision tree model for diagnosis of pancreatic cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 1911-1915

  Qian, Jing Yi ^a   Mou, Si Hua ^b   Liu, Chi Bo ^b  

^a Medical Services Section   (China)

^b TAIZHOU MUNICIPAL HOSPITAL   (China)

Author keywords

Biomarker; Diagnosis; Pancreatic cancer; Protein; SELDI TOF MS

Indexed keywords

PLASMA PROTEIN; TUMOR MARKER;

AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CHRONIC PANCREATITIS; COMPARATIVE STUDY; DECISION TREE; FEMALE; HUMAN; IMMUNOMAGNETIC SEPARATION; MAGNETISM; MALE; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PANCREAS; PANCREAS TUMOR; PROGNOSIS;

AGED; BLOOD PROTEINS; CASE-CONTROL STUDIES; DECISION TREES; FEMALE; HUMANS; IMMUNOMAGNETIC SEPARATION; MAGNETICS; MALE; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PROGNOSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84872676125     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.1911     Document Type: Article

References (20)

1. Adam BL, Qu Y, Davis JW, et al (2002). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res, 62, 3609-14.
2. DiMagno EP, Reber HA, Tempero MA (1999). Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology, 117, 1463-84.
3. Ebert MP, Meuer J, Wiemer JC, et al (2004). Identification of gastric cancer patients by serum protein profiling. J Proteome Res, 3, 1261-6.
4. Guo R, Pan C, Shen J, et al (2011). New serum biomarkers for detection of esophageal carcinoma using Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Cancer Res Clin Oncol, 137, 513-9.
5. Hortin GL (2006). The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem, 52, 1223-37.
6. Liu C, Pan C, Shen J, et al (2011). MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of colorectal cancer. Int J Med Sci, 8, 39-47.
7. Liu C, Wang H, Pan C, et al (2010). Serum protein fingerprint of patients with gastric cancer by SELDI technology. African J Biotechnol, 9, 2298-304.
8. Kim JE, Lee KT, Lee JK, et al (2004). Clinical usefulness of Carbohydrate antigen 199 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol, 19, 182-6.
9. Kim EJ, Simeone DM, (2011). Advances in pancreatic cancer. Curr Opin Gastroenterol, 27, 460-6.
10. Liang Y, Fang M, Li J, et al (2006). Serum proteomic patterns for gastric lesions as revealed by SELDI mass spectrometry. Exp Mol Pathol, 81, 176-80.
11. Li D, Xie K, Wolff R, et al (2004). Pancreatic cancer. Lancet, 363, 1049-57.
12. Liotta LA, Ferrari M, Petricoin E (2003). Clinical proteomics: written in blood. Nature, 425, 905.
13. Liu CB, Liang Y, Pan CQ, et al (2009). Proteome study of differential protein expression in HBV-related primary hepatic carcinoma. Chem J Chinese Universities, 30, 1763-6.
14. Liu C, Shen J, Pan C, et al (2010). MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma. Am J Clin Pathol, 134, 235-41
15. Schwegler EE, Cazares L, Steel LF, et al (2005) SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology, 41, 634-42.
16. Semmes OJ, Feng Z, Adam BL, et al (2005). Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem, 51, 102-12.
17. Singh S, Tang SJ, Sreenarasimhaiah J, et al (2011). The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci, 56, 2491-6.
18. Wagner M, Naik DN, Pothen A, et al (2004). Computational protein biomarker prediction: a case study for prostate cancer. BMC Bioinformatics, 5, 26.
19. Ward DG, Cheng Y, N'Kontchou G, et al (2006). Preclinical and post-treatment changes in the HCC-associated serum proteome. Br J Cancer, 95, 1379-83.
20. Ward DG, Suggett N, Cheng Y, et al (2006). Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer, 94, 1898-905.